<p>Pregnancy Category D. Use of drugs that act on the renin-angiotensin&nbsp;system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and&nbsp;neonatal&nbsp;morbidity and death. Resulting&nbsp;oligohydramnios&nbsp;can be associated with fetal lung&nbsp;hypoplasia&nbsp;and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria,&nbsp;hypotension, renal failure, and death. When pregnancy is detected, discontinue Telmisartan and hydrochlorothiazide as soon as possible.<br />
<br />
Nursing Mothers: It is not known whether telmisartan is excreted in human milk, but telmisartan was shown to be present in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>